BioMedWire Stocks

Hantavirus Fatalities on Cruise Ship Draw Attention to This Little-Known Infection

The media is awash with news that a cruise ship, called MV Hondius, has suffered an outbreak of hantavirus. Three fatalities have occurred, with one victim confirmed to have died from this infection. Many people are wondering what this infection is and what they can do to stay safe or what they can do in case they are infected. We provide an explainer of the basics you need to know about this virus. 

For starters, hantavirus is transmitted by rodents like mice and rats. Infections resulting from this virus are rare in humans, and when they happen, they fall into one of two categories. 

The first is the Old World hantavirus. This family of viruses typically occurs in Asia and Europe. A person infected by this family of hantavirus develops hemorrhagic fever characterized by renal syndrome. The person experiences intense headaches, fever, abdominal and back pain, and may suffer damage to their kidneys. 

The second category is the New World hantavirus, mostly occurring in the Americas. They trigger a pulmonary syndrome linked to the virus. The infection starts with symptoms similar to what flu triggers, such as fatigue, muscle aches and fever. These symptoms progress rapidly into respiratory failure and acute pulmonary syndrome. 

Hantaviruses are spread when someone inhales or comes into contact with rodent feces that are infected. Infected saliva and urine of these rodents can also transmit the virus. In rare cases, being scratched or bitten by an infected rodent can also transmit this virus into your bloodstream. Under normal circumstances, these viral infections are hardly transmitted from one person to another in the same way that infections like COVID-19 or flu are transmitted. 

The incubation period of these viruses tends to be long, ranging from 1–8 weeks. This raises questions about how the infection started on the cruise ship. Scientists are speculating that someone or several people may have been infected before they boarded the ship, or the ship itself was infested with rodents that had the virus, leading to the people on board getting exposed in the ways mentioned earlier. Infection from one person to another, though unlikely, could also be a possibility. An ongoing investigation will shed some light on the source of the infection. 

Currently, there are no treatments indicated for hantavirus infections. Instead, patients are given supportive management. For example, those manifesting pulmonary syndrome can be put on oxygen, ventilation, blood pressure management and fluid management. 

Mortality can be up to 15% in the case of Old World hantavirus infections, while this can be up to 40% for the pulmonary version of this infection linked to New World hantavirus infections. This high mortality makes early detection pivotal since patients can get the help they need before symptom progression gets critical and endangers lives. 

Risks like hantaviruses make the work of companies like Co-Diagnostics Inc. (NASDAQ: CODX) that develop diagnostic systems and kits very important, especially when suspected cases are flagged in the field where access to advanced lab settings is limited for accurate diagnosis. 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…

5 hours ago

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies 

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…

11 hours ago

As Cases of Measles Rise, US Officials Double Down on Contact Tracing and Vaccination

As July came to an end, the United States reached an undesirable milestone: exceeding the…

1 day ago

Climate Change is Accelerating the Spread of Infectious Diseases, Experts Warn

Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…

5 days ago

Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment

Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months…

6 days ago

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The…

1 week ago